Toward this end, we have assessed the therapeutic potential of TMZ’s synergistic administration with MTX on the RA model by examining the expression of TLR4 and MYD88, but also its downstream level of TRAF6 and IRAK in the paw tissue of the FCA-induced RA model. The gene discussed is MYD88; the disease is rheumatoid arthritis.